Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1972 2
1973 6
1974 9
1975 7
1976 5
1977 4
1978 3
1979 7
1980 5
1981 3
1982 4
1983 4
1984 5
1985 7
1986 4
1987 4
1988 3
1989 5
1990 8
1991 7
1992 7
1993 13
1994 6
1995 10
1996 8
1997 6
1998 7
1999 3
2000 3
2001 5
2002 3
2003 1
2004 3
2005 6
2006 10
2007 6
2008 7
2009 9
2010 2
2011 5
2012 5
2013 7
2014 9
2015 8
2016 2
2017 5
2018 6
2019 6
2020 11
2021 12
2022 7
2023 10
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

293 results

Results by year

Filters applied: . Clear all
Page 1
S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11).
Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. Cornberg M, et al. Z Gastroenterol. 2021 Jul;59(7):691-776. doi: 10.1055/a-1498-2512. Epub 2021 Jul 12. Z Gastroenterol. 2021. PMID: 34255317 Free article. German. No abstract available.
A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.
van Bömmel F, Stein K, Heyne R, Petersen J, Buggisch P, Berg C, Zeuzem S, Stallmach A, Sprinzl M, Schott E, Pathil-Warth A, von Arnim U, Keitel V, Lohmeyer J, Simon KG, Trautwein C, Trein A, Hüppe D, Cornberg M, Lammert F, Ingiliz P, Zachoval R, Hinrichsen H, Zipprich A, Klinker H, Schulze Zur Wiesch J, Schmiedeknecht A, Brosteanu O, Berg T. van Bömmel F, et al. Among authors: sprinzl m. J Hepatol. 2023 May;78(5):926-936. doi: 10.1016/j.jhep.2022.12.018. Epub 2023 Mar 28. J Hepatol. 2023. PMID: 37062574 Free article. Clinical Trial.
Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.
Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Hüser N, Durantel D, Liang TJ, Münk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U. Lucifora J, et al. Among authors: sprinzl mf. Science. 2014 Mar 14;343(6176):1221-8. doi: 10.1126/science.1243462. Epub 2014 Feb 20. Science. 2014. PMID: 24557838 Free PMC article.
Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.
Dietz-Fricke C, Tacke F, Zöllner C, Demir M, Schmidt HH, Schramm C, Willuweit K, Lange CM, Weber S, Denk G, Berg CP, Grottenthaler JM, Merle U, Olkus A, Zeuzem S, Sprinzl K, Berg T, van Bömmel F, Wiegand J, Herta T, Seufferlein T, Zizer E, Dikopoulos N, Thimme R, Neumann-Haefelin C, Galle PR, Sprinzl M, Lohse AW, Schulze Zur Wiesch J, Kempski J, Geier A, Reiter FP, Schlevogt B, Gödiker J, Hofmann WP, Buggisch P, Kahlhöfer J, Port K, Maasoumy B, Cornberg M, Wedemeyer H, Deterding K. Dietz-Fricke C, et al. Among authors: sprinzl m. JHEP Rep. 2023 Mar 15;5(4):100686. doi: 10.1016/j.jhepr.2023.100686. eCollection 2023 Apr. JHEP Rep. 2023. PMID: 37025462 Free PMC article.
Immune control of hepatitis B virus.
Bauer T, Sprinzl M, Protzer U. Bauer T, et al. Among authors: sprinzl m. Dig Dis. 2011;29(4):423-33. doi: 10.1159/000329809. Epub 2011 Aug 30. Dig Dis. 2011. PMID: 21894014 Review.
RNA aptamers directed against oligosaccharides.
Sprinzl M, Milovnikova M, Voertler CS. Sprinzl M, et al. Handb Exp Pharmacol. 2006;(173):327-40. doi: 10.1007/3-540-27262-3_16. Handb Exp Pharmacol. 2006. PMID: 16594623 Review.
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
Dietz J, Müllhaupt B, Buggisch P, Graf C, Peiffer KH, Matschenz K, Schattenberg JM, Antoni C, Mauss S, Niederau C, Discher T, Trauth J, Dultz G, Schulze Zur Wiesch J, Piecha F, Klinker H, Müller T, Berg T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; German HCV Resistance Study Group; University Hospitals; Academic Hospitals; Local study sites (private practices), Germany. Dietz J, et al. J Hepatol. 2023 Jan;78(1):57-66. doi: 10.1016/j.jhep.2022.08.016. Epub 2022 Aug 27. J Hepatol. 2023. PMID: 36031158
Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort.
Shi Y, Strobl R, Apfelbacher C, Bahmer T, Geisler R, Heuschmann P, Horn A, Hoven H, Keil T, Krawczak M, Krist L, Lemhöfer C, Lieb W, Lorenz-Depiereux B, Mikolajczyk R, Montellano FA, Reese JP, Schreiber S, Skoetz N, Störk S, Vehreschild JJ, Witzenrath M, Grill E; NAPKON Study Group. Shi Y, et al. Infection. 2023 Dec;51(6):1679-1694. doi: 10.1007/s15010-023-02043-6. Epub 2023 May 25. Infection. 2023. PMID: 37231313 Free PMC article.
A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura.
Falter T, Rossmann H, de Waele L, Dekimpe C, von Auer C, Müller-Calleja N, Häuser F, Degreif A, Marandiuc D, Messmer X, Sprinzl M, Lackner KJ, Jurk K, Vanhoorelbeke K, Lämmle B. Falter T, et al. Among authors: sprinzl m. Blood Adv. 2023 Sep 12;7(17):5091-5102. doi: 10.1182/bloodadvances.2023010028. Blood Adv. 2023. PMID: 37399489 Free PMC article.
293 results